165 related articles for article (PubMed ID: 18682270)
1. Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.
Fletcher HA; Pathan AA; Berthoud TK; Dunachie SJ; Whelan KT; Alder NC; Sander CR; Hill AV; McShane H
Vaccine; 2008 Sep; 26(41):5269-75. PubMed ID: 18682270
[TBL] [Abstract][Full Text] [Related]
2. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.
McShane H; Pathan AA; Sander CR; Keating SM; Gilbert SC; Huygen K; Fletcher HA; Hill AV
Nat Med; 2004 Nov; 10(11):1240-4. PubMed ID: 15502839
[TBL] [Abstract][Full Text] [Related]
3. Process of assay selection and optimization for the study of case and control samples from a phase IIb efficacy trial of a candidate tuberculosis vaccine, MVA85A.
Harris SA; Satti I; Matsumiya M; Stockdale L; Chomka A; Tanner R; O'Shea MK; Manjaly Thomas ZR; Tameris M; Mahomed H; Scriba TJ; Hanekom WA; Fletcher HA; McShane H
Clin Vaccine Immunol; 2014 Jul; 21(7):1005-11. PubMed ID: 24828094
[TBL] [Abstract][Full Text] [Related]
4. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations.
Beveridge NE; Price DA; Casazza JP; Pathan AA; Sander CR; Asher TE; Ambrozak DR; Precopio ML; Scheinberg P; Alder NC; Roederer M; Koup RA; Douek DC; Hill AV; McShane H
Eur J Immunol; 2007 Nov; 37(11):3089-100. PubMed ID: 17948267
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
Whelan KT; Pathan AA; Sander CR; Fletcher HA; Poulton I; Alder NC; Hill AV; McShane H
PLoS One; 2009 Jun; 4(6):e5934. PubMed ID: 19529780
[TBL] [Abstract][Full Text] [Related]
6. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.
Verreck FA; Vervenne RA; Kondova I; van Kralingen KW; Remarque EJ; Braskamp G; van der Werff NM; Kersbergen A; Ottenhoff TH; Heidt PJ; Gilbert SC; Gicquel B; Hill AV; Martin C; McShane H; Thomas AW
PLoS One; 2009; 4(4):e5264. PubMed ID: 19367339
[TBL] [Abstract][Full Text] [Related]
7. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.
Scriba TJ; Tameris M; Mansoor N; Smit E; van der Merwe L; Mauff K; Hughes EJ; Moyo S; Brittain N; Lawrie A; Mulenga H; de Kock M; Gelderbloem S; Veldsman A; Hatherill M; Geldenhuys H; Hill AV; Hussey GD; Mahomed H; Hanekom WA; McShane H
J Infect Dis; 2011 Jun; 203(12):1832-43. PubMed ID: 21606542
[TBL] [Abstract][Full Text] [Related]
8. Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A.
Tanner R; Kakalacheva K; Miller E; Pathan AA; Chalk R; Sander CR; Scriba T; Tameris M; Hawkridge T; Mahomed H; Hussey G; Hanekom W; Checkley A; McShane H; Fletcher HA
BMC Infect Dis; 2014 Dec; 14():660. PubMed ID: 25466778
[TBL] [Abstract][Full Text] [Related]
9. Heterologous vaccination against human tuberculosis modulates antigen-specific CD4+ T-cell function.
Dintwe OB; Day CL; Smit E; Nemes E; Gray C; Tameris M; McShane H; Mahomed H; Hanekom WA; Scriba TJ
Eur J Immunol; 2013 Sep; 43(9):2409-20. PubMed ID: 23737382
[TBL] [Abstract][Full Text] [Related]
10. Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A.
Griffiths KL; Pathan AA; Minassian AM; Sander CR; Beveridge NE; Hill AV; Fletcher HA; McShane H
PLoS One; 2011; 6(8):e23463. PubMed ID: 21887254
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
Satti I; Meyer J; Harris SA; Manjaly Thomas ZR; Griffiths K; Antrobus RD; Rowland R; Ramon RL; Smith M; Sheehan S; Bettinson H; McShane H
Lancet Infect Dis; 2014 Oct; 14(10):939-46. PubMed ID: 25151225
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.
Hawkridge T; Scriba TJ; Gelderbloem S; Smit E; Tameris M; Moyo S; Lang T; Veldsman A; Hatherill M; Merwe Lv; Fletcher HA; Mahomed H; Hill AV; Hanekom WA; Hussey GD; McShane H
J Infect Dis; 2008 Aug; 198(4):544-52. PubMed ID: 18582195
[TBL] [Abstract][Full Text] [Related]
13. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
[TBL] [Abstract][Full Text] [Related]
14. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
McShane H; Pathan AA; Sander CR; Goonetilleke NP; Fletcher HA; Hill AV
Tuberculosis (Edinb); 2005; 85(1-2):47-52. PubMed ID: 15687027
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis.
Tchilian EZ; Desel C; Forbes EK; Bandermann S; Sander CR; Hill AV; McShane H; Kaufmann SH
Infect Immun; 2009 Feb; 77(2):622-31. PubMed ID: 19064635
[TBL] [Abstract][Full Text] [Related]
16. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis.
Vordermeier HM; Villarreal-Ramos B; Cockle PJ; McAulay M; Rhodes SG; Thacker T; Gilbert SC; McShane H; Hill AV; Xing Z; Hewinson RG
Infect Immun; 2009 Aug; 77(8):3364-73. PubMed ID: 19487476
[TBL] [Abstract][Full Text] [Related]
17. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells.
Scriba TJ; Tameris M; Mansoor N; Smit E; van der Merwe L; Isaacs F; Keyser A; Moyo S; Brittain N; Lawrie A; Gelderbloem S; Veldsman A; Hatherill M; Hawkridge A; Hill AV; Hussey GD; Mahomed H; McShane H; Hanekom WA
Eur J Immunol; 2010 Jan; 40(1):279-90. PubMed ID: 20017188
[TBL] [Abstract][Full Text] [Related]
18. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K
Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518
[TBL] [Abstract][Full Text] [Related]
19. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
Goonetilleke NP; McShane H; Hannan CM; Anderson RJ; Brookes RH; Hill AV
J Immunol; 2003 Aug; 171(3):1602-9. PubMed ID: 12874255
[TBL] [Abstract][Full Text] [Related]
20. Heterologous priming-boosting immunization of cattle with Mycobacterium tuberculosis 85A induces antigen-specific T-cell responses.
Taracha EL; Bishop R; Musoke AJ; Hill AV; Gilbert SC
Infect Immun; 2003 Dec; 71(12):6906-14. PubMed ID: 14638779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
